<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447797</url>
  </required_header>
  <id_info>
    <org_study_id>HM-IBAT-104</org_study_id>
    <nct_id>NCT01447797</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin</brief_title>
  <official_title>Single Dose Open-label Comparative Pharmacokinetic Study to Assess the Pharmacokinetic Characteristics of Irbesartan and Atorvastatin Between Irbesartan/Atorvastatin Combination Tablet and Coadministration of Irbesartan and Atorvastatin Tablets in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics and safety after oral
      administration of Irbesartan and Atorvastatin in combination as HCP0912
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of Irbesartan</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Atorvastatin and 2-hydroxy atorvastatin</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Irbesartan</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Atorvastatin and 2-hydroxy atorvastatin</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HCP0912</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irbesartan/Atorvastatin combination tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irbesartan and Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coadministration of irbesartan and atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP0912 / Irbesartan and Atorvastatin</intervention_name>
    <description>Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin</description>
    <arm_group_label>HCP0912</arm_group_label>
    <arm_group_label>Irbesartan and Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 45

          -  Signed informed consent form

          -  weight : over 45kg and in the range of Â±20% of IBW

        Exclusion Criteria:

          -  Has a medical history of hypersensitivity to atorvastatin or irbesartan

          -  severe Hypotension

          -  Not eligible for subject in health examination within 28 days of IP administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>April 1, 2012</last_update_submitted>
  <last_update_submitted_qc>April 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irbesartan</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>combination</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

